Comparing Antipsychotic Medications in LBD Over Time
A Pragmatic Randomized Trial Comparing Antipsychotics in Lewy Body Disease
The University of Texas Health Science Center at San Antonio
94 participants
Apr 22, 2022
INTERVENTIONAL
Conditions
Summary
The primary objective of this study is to determine whether treatment with pimavanserin or quetiapine is associated with a greater improvement in psychosis when used in a routine clinical setting to treat hallucinations and/or delusions due to Parkinson's disease (PD) or dementia with Lewy bodies (DLB) - collectively referred to as Lewy body disease (LBD).
Eligibility
Inclusion Criteria5
- Patients seen in the neurology clinic at UT Health San Antonio
- Diagnosed with psychosis due to PD or DLB
- Requiring initiation of an antipsychotic medication
- Clinical equipoise between quetiapine and pimavanserin must exist
- The prescribing provider must be comfortable prescribing and managing both quetiapine and pimavanserin
Exclusion Criteria4
- Medical contraindication to either medication
- Caregiver unavailable to complete NPI-Q
- Currently taking an antipsychotic medication
- Prescribing provider unwilling to manage either medication
Interventions
Dosage choice and further medication management will be at the discretion of the treating clinician, per routine clinical practice.
Dosage choice and further medication management will be at the discretion of the treating clinician, per routine clinical practice.
Locations(2)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT05590637